Pharmacological evaluation of novel 5-HT 3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery

MLA

Deepali Gupta, et al. “Pharmacological Evaluation of Novel 5-HT 3 Receptor Antagonist, QCM-13 (N-Cyclohexyl-3-Methoxyquinoxalin-2-Carboxamide) as Anti-Anxiety Agent in Behavioral Test Battery.” Journal of Pharmacy and Bioallied Sciences, vol. 7, no. 2, Jan. 2015, pp. 103–08. EBSCOhost, https://doi.org/10.4103/0975-7406.154429.

APA

Deepali Gupta, Mahesh Radhakrishnan, Devadoss Thangaraj, & Yeshwant Kurhe. (2015). Pharmacological evaluation of novel 5-HT 3 receptor antagonist, QCM-13 (N-cyclohexyl-3-methoxyquinoxalin-2-carboxamide) as anti-anxiety agent in behavioral test battery. Journal of Pharmacy and Bioallied Sciences, 7(2), 103–108. https://doi.org/10.4103/0975-7406.154429

Chicago

Deepali Gupta, Mahesh Radhakrishnan, Devadoss Thangaraj, and Yeshwant Kurhe. 2015. “Pharmacological Evaluation of Novel 5-HT 3 Receptor Antagonist, QCM-13 (N-Cyclohexyl-3-Methoxyquinoxalin-2-Carboxamide) as Anti-Anxiety Agent in Behavioral Test Battery.” Journal of Pharmacy and Bioallied Sciences 7 (2): 103–8. doi:10.4103/0975-7406.154429.